Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 4/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 4/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | WNT3 | P56703 | 1/20 | 0.34 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16082361 | 1.00 | KLK7 (0.34) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL8002408 | 0.93 | FKBP1A (0.36) | FKBP1AMEN1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL862733 | 0.87 | MEN1 (0.39) | WNT3SFRP1CHRM2CHRM1CHRM3 | |
| SCHEMBL946514 | 0.87 | MEN1 (0.39) | WNT3SFRP1CHRM2CHRM1CHRM3 | |
| SCHEMBL903617 | 0.87 | MEN1 (0.39) | WNT3SFRP1CHRM2CHRM1CHRM3 | |
| SCHEMBL23490181 | 0.84 | KLK7 (0.36) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL1568510 | 0.83 | ALDH1A1 (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL8002411 | 0.83 | SPHK1 (0.34) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL28246446 | 0.83 | ACE (0.39) | CHRM2CHRM1CHRM3MEN1ALDH1A1 | |
| SCHEMBL12105456 | 0.82 | CHRM2 (0.41) | KLK7WNT3SFRP1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010126820-A2 | PREPARATION OF ALKYL ESTERS OF N-PROTECTED OXO-AZACYCLOALKYLCARBOXYLIC ACIDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| EP-1713822-B1 | HCV NS-3 SERINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-7608590-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2009-10-27 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1173169-A4 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | KLK7 1999/4885KLK5 3207/4885PRSS1 4/4885 |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | KLK7 4231/4885KLK5 4470/4885PRSS1 38/4885 |
| US-20070161574-A1 | Hcv ns-3 serine protease inhibitors | PRSS1, HPN, SPINT2 | KLK7 2289/4885KLK5 3084/4885PRSS1 1/4885 |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | KLK7 4366/4885KLK5 3374/4885PRSS1 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.